A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (NCT05424822)
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants With NHL and CLL
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D\[s\]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to further characterize the safety of JNJ-80948543 at the putative RP2D(s) in Part B (Cohort Expansion).
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- City of Hope — Duarte, California
- Icahn School of Medicine at Mount Sinai — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Sarah Cannon Research Institute — Nashville, Tennessee
- The University of Texas MD Anderson Cancer Center — Houston, Texas
- Texas Transplant Institute — San Antonio, Texas
- Seattle Cancer Care Alliance — Seattle, Washington
- Macquarie University Hospital — Macquarie University,
- The Alfred Hospital — Melbourne,
- Linear Clinical Research Ltd — Nedlands,
- Scientia Clinical Research — Randwick,
- Chongqing University Cancer Hospital — Chongqing,
- Sun Yat Sen University Cancer Center — Guangzhou,
- Tianjin cancer hospital — Tianjin,
- Union Hospital Tongji Medical College of Huazhong University of Science and Technology — Wuhan,
- Rigshospitalet — Copenhagen,
- Odense University Hospital — Odense,
- CHRU de Lille Hopital Claude Huriez — Lille,
- Institut Curie — Paris,
- Institut de Cancerologie Strasbourg Europe ICANS — Strasbourg,
- Institut Universitaire du cancer de Toulouse-Oncopole — Toulouse,
- Carmel Medical Center — Haifa,
- Hadassah Medical Center — Jerusalem,
- Tel Aviv Sourasky Medical Center — Tel Aviv,
- National Cancer Center Hospital East — Kashiwa,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Lymphoma, Non-Hodgkin
- NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers — Denver, Colorado
- A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) — Santa Monica, California
- A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma — Duarte, California
- Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma — St Louis, Missouri
- A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma — Pasadena, California
Explore by condition: All Lymphoma, Non-Hodgkin clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.